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Quantifying the association between adherence and the growth response to growth hor-
mone (GH) treatment is hampered by suboptimal methods of measuring adherence, con-
founders associated with the growth response, and restriction of the outcome parameters to
yearly growth velocities.
Aim
To investigate the effect of adherence on the two-year growth response to GH treatment in
prepubertal children with idiopathic isolated growth hormone deficiency (GHD) participating
in the easypod connect observational study (ECOS), a 5-year, Phase IV open-label study to
continuously assess real-world adherence via the easypod electronic drug-delivery device.
Patients and methods
Outcome measures were change in height standard deviation score (ΔHSDS), index of
responsiveness (IoR), and parameters of two catch-up growth (CUG) curve functions
(monomolecular growth curve and second degree polynomial) with adj-HSDS (HSDS minus
Target height (TH) SDS) as dependent variable. Inclusion criteria were GHD, naïve to GH
treatment, known TH, age <10y in girls and <12y in boys,�3 measurements, HSDS <-2 at
start, complete data on growth and adherence in the first and second year. Linear regres-
sion analyses were performed to test the association between adherence (continuous and
high vs. low) and the outcome measures, also adjusted for potential clinical confounders
(age at start, adj-HSDS at start, birth weight SDS, gestational age (<37 weeks vs�37
weeks), GH dose, GH max (n = 58)). The formula of IoR already adjusts for confounders.
Results
In total, 95 patients complied with the inclusion criteria. The strongest associations were
found between high adherence in the second year (�91% as cut-off value) and IoR 2y
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(+0.62), and average adherence and high adherence (�78%) in the first two years and
ΔHSDS 0-2y (+0.11 SD per 1 injection/week, and +0.34 SD for high vs. low adherence).
Conclusion
Suboptimal adherence negatively affected the growth response in the first two years of GH
treatment.
Introduction
Growth hormone (GH) treatment for children with GH deficiency (GHD) is efficacious in
generating catch-up growth (CUG) in the first years of treatment, usually followed by a main-
tenance phase and finally leading to a height close to the target height (TH) [1,2]. However,
the growth response has been shown to be quite variable. Several groups have investigated the
clinical features associated with the growth response [3,4,5,6], and in general approximately
50% of the variance could be explained by features like the severity of GHD (as assessed by the
GH peak in provocation tests), age, bone age delay, birth weight, etc [7].
None of these prediction models could include adherence into their models, because there
were no tools to assess adherence accurately. However, several studies have shown that adher-
ence has an important effect on growth on GH treatment [8,9,10,11,12], although they could
only be conducted over short time periods, and using a methodology based on self-reporting
or number of issued and renewed prescriptions.
There are several challenges in studying the association between adherence to growth hor-
mone (GH) treatment versus the growth response to GH. The first challenge is to make a deci-
sion on which growth parameter is the most suitable outcome parameter. So far, most studies
investigating predictive factors have used yearly growth velocity data, particularly first year’s
height velocity [3,6]. Others have used the change in height Standard Deviation Score (HSDS)
(delta HSD, ΔHSDS) over 1 or 2 years [4,5]. All these parameters depend on the age and height
SDS at start of treatment, and do not fully represent the actual shape of the catch-up growth
(CUG) in the first years of GH treatment in children with GHD. The second challenge is that,
besides adherence, there are many other clinical parameters that influence the growth response
to GH, as illustrated by the various prediction models [7]. So, in order to obtain an unbiased
effect of adherence, it is necessary to adjust for important clinical predictors that are confound-
ers in an analysis of the effect of adherence on the growth response to GH. The third challenge
is to find a reliable method for measuring adherence.
In this study we accounted for these challenges. First, we used a novel way of expressing
CUG on GH treatment, using mathematical models of HSDS (adjusted for TH]) over two
years of GH treatment. In an earlier study, we showed that mathematical modelling of CUG
with the monomolecular growth curve is suitable for celiac disease [13]. A second degree poly-
nomial was also used, because for most children the shape of the HSDS in the first two years is
a catch-up in growth followed by stabilization. Second, we entered important potential con-
founders into the models. Third, we used a novel electronic tool to assess adherence accurately
(easypod) [14,15,16]. For this purpose we used data from children naïve to GH treatment par-
ticipating in the ECOS study, using automated continuous assessment of adherence through
easypod. The easypod Connect observational study (ECOS) is a 5-year, Phase IV open label
study that started in 2010 in 24 countries to assess ‘real-world’ adherence via the easypod elec-
tronic drug delivery device.[17]
Effect of adherence to growth hormone treatment on growth
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The data collection was performed via the
easypodTM electronic drug-delivery device, which
is a product of Merck KGaA. Also, physician data
entry of outcome measures were retrospectively
and prospectively collected by Merck KGaA. This
data collection was part of the ECOS study, which
was conducted in accordance with the principles of
the Declaration of Helsinki, Good Clinical Practice
(ICH-GCP E6) guidelines and applicable national
Methods
Data
Adherence data were derived from the easypod device combined with physician data entry of
outcome measures. Data were collected retrospectively and prospectively. Collected data were
analyzed in a multinational pooled analysis.
Inclusion criteria for the ECOS study were: GH administered via the easypod electrome-
chanical device; under 18 years of age, or over 18 without fusion of growth plates; parent’s or
guardian’s written informed consent, given before entering data into the registry/observational
study (if the child was old enough to read and write, a separate assent form was given as
defined in the appropriate jurisdiction of each country). Exclusion criteria for the ECOS study
were: Subjects taking GH in whom growth plates have fused (i.e. taking GH for its metabolic
effects); contra-indications to Saizen GH; Use of an investigational drug or participation in
another interventional clinical study. The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki, Good Clinical Practice (ICH-GCP E6) guidelines and
applicable national legal and regulatory requirements.
To investigate the effect of adherence on the two-year growth response to GH treatment in
prepubertal children with idiopathic isolated growth hormone deficiency (GHD) in the ECOS
study, the following selection criteria were applied:
• Naïve to GH treatment
• Patients diagnosed with Idiopathic Isolated GHD by their physicians
• Known parental heights, so that TH could be calculated
• Age at end of 2 year study period <10 years in girls and <12 years in boys (i.e. before onset
of puberty)
• At least three measurements of height available from start treatment
• HSDS <-2.0 at start treatment
• At least two data measurements on growth and adherence in the first and second year after
start of treatment
The age limit was used for two reasons. First, we wished to limit the analysis to prepubertal
children, because insufficient data were available in the database about pubertal status during
GH treatment. Second, beyond these age limits the SD of the population’s growth reference
charts shows a non-linear pattern of an increase followed by a decrease, due to the varying
ages at pubertal onset in the general population. Because HSDS is the main outcome parameter
in our analysis, a higher cut-off for age would generate noise and bias.
Statistical analyses
Adherence was calculated as the number of injections received divided by the number of
planned injections during the considered period, expressed as a percentage. All adherence rate
analyses were based on periods of complete weeks. Data are presented over the first two years.
Outcome measures for the growth response to GH treatment in the first two years were:
• Change in HSDS in the first (ΔHSDS 0–1 y), second (ΔHSDS 1–2 y) and first two years
(ΔHSDS 0–2 y)
• Index of responsiveness (IoR) in the first and second year [3], where IoR first year = (height
velocity first year-(12.41–0.36�Age at start GH+0.47� Birthweight SDS+1.54�(log(3�GH dose
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at start GH (mg/kg/wk)))-0.6�(HSDS 1y-TH SDS)+0.28�weight SDS 1y))/1.72, and IoR sec-
ond year = (height velocity second year-(5.69–0.09�Age at start GH+0.63�(log(3�GH dose at
start GH (mg/kg/wk)))+0.24�weight SDS 2y+0.31� height velocity first year))/1.19
• Parameters of the monomolecular growth curve for catch-up growth [13]: Monomolecular
growth curve: adj-HSDS = A � (1—B � exp(-k � x))– 5, with x age after start GH
• Parameters of a second degree polynomial: second degree polynomial: adj-HSDS = c + D�x
+ E�x2, with x age after start GH
Mixed-effect models were used to fit the monomolecular growth curve and the second
degree polynomial on adj-HSDS (HSDS minus TH-SDS). Each curve summarizes the first
phase of CUG in three parameters. For the monomolecular growth curve, these parameters
are A-5 = attained adj-HSDS after two years, A�(1-B)-5 = adj-HSDS at start, k = growth rate.
For the second degree polynomial, these are c = intercept (adj-HSDS at start), D = slope
(CUG), E = deceleration (deceleration part after CUG). A higher value of D implies a steeper
curve between 0–2 years and a higher value of E implies a stronger CUG after approximately 1
year. If E>0, then there is a stronger CUG in the second year, and if E<0 then CUG is stron-
ger in the first year.
Linear regression analyses were performed to test the association between adherence in the
first, second, and the first two years and the outcome measures. Adherence is highly skewed
with peak values near or at 100%. We therefore analyzed this independent variable both as a
continuous variable and categorized into a high and low level. Recursive partitioning [18] in
software R (package rpart) was used to find the cut-off point (the first split) for high and low
adherence that maximizes the correlation between adherence and height gain.
The parameter B from the monomolecular growth curve and c from the second degree
polynomial were not used in the analyses as outcome measures, because these are related to
the adj-HSDS at start and only of interest as a potential confounder. We adjusted the associa-
tions for potential clinical confounders that were significantly related to adherence in the first,
second or first two years. The potential clinical confounders were age at start, adj-HSDS at
start (observed data, not derived from the monomolecular growth curve model), birth weight
SDS, gestational age (<37 weeks vs.�37 weeks), GH dose, and GH max. The formula of IoR
already adjusts for confounders. We, therefore, did not adjust the IoR for the potential clinical
confounders. HSDS at exactly 1.0 and 2.0y were obtained by linear interpolation using the
nearest measurements around these ages. WHO growth references were used to calculate the
SDS values. These references were obtained from the WHO Multicentre Growth Reference
Study (MGRS) (ages 0–5 years) and the WHO 2007 reference (5–19 years for height) [19].
TH-SDS was calculated as 0.72 x (father’s HSDS + mother’s HSDS)/2 [20]. This definition cor-
rects for assortative mating and parent-offspring correlations. We also used the first and sec-
ond year Index of Responsiveness (IoR) for the KIGS prediction model as outcome measures
[3], but using the WHO references for weight SDS at birth.
Results
Fig 1 shows the sample size of this study after applying the inclusion criteria. In total 490 naïve
patients with GHD were available within the ECOS study. The sample size of patients with an
Organic GH deficiency (OGHD) due to congenital/anatomical or tumor origin was low and
therefore excluded from the analysis in order to analyse a homogeneous group. In total, 95
patients with Idiopathic Isolated GH deficiency (IIGHD) were available for analysis. Table 1
shows the descriptive statistics of the background characteristics and the clinical parameters of
Effect of adherence to growth hormone treatment on growth
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these 95 patients. Although one patient exceeded the (arbitrary) cut-off of 10 ug/L at the GH
peak after stimulation (GH peak-1 = 9.97 and GH peak -2 = 12.5 ug/L), we included this
patient in our study because the treating physician interpreted this patient as GHD.
Fig 2 shows the median and P25-75 adherence % in the first two years of GH treatment. In
the first year, median adherence was high with relatively little variation. In the second year,
median adherence decreased, while the variation increased. Recursive partitioning for adher-
ence resulted in a split at�98% in the first year,�91%, in the second year, and�78% in the
Fig 1. Selection criteria within the ECOS study.
https://doi.org/10.1371/journal.pone.0206009.g001
Table 1. Background characteristics and clinical parameters of the sample (n = 95).
Characteristics Mean (SD) Median (min, max) N (%)
Sex (male) 72 (76%)
Gestational age (<37 wks) 12 (13%)
Birth weight SDS -1.0 (1.5) -0.9 (-6.4, 1.2)
Age at start 6.3 (2.1) 6.2 (1.3, 10.0)
HSDS at start -2.8 (0.7) -2.6 (-5.6, -2.0)
HSDS 1y after start GH -2.1 (0.7) -2.0 (-4.4, -1.0)
HSDS 2y after start GH -1.7 (0.7) -1.6 (-4.2, -0.3)
Adj-HSDS at start -2.1 (0.9) -2.1 (-4.7, -0.1)
Adj-HSDS 1y after start GH -1.4 (0.8) -1.4 (-4.0, 0.2)
Adj-HSDS 2y after start GH -1.1 (0.8) -1.1 (-3.6, 0.5)
Weight SDS at start -1.8 (1.1) -1.9 (-5.2, 1.8)
GH dose (mg/kg/wk) 0.21 (0.10) 0.21 (0.04, 0.83)
GH max� 4.9 (3.0) 4.3 (0.47, 12.5)
IoR first year -0.4 (1.1) -0.5 (-3.4, 4.1)
IoR second year -0.1 (1.1) -0.1 (-3.5, 3.1)
Adherence 0-1y 80.8 (31.1) 95.1 (0, 100)
Adherence 1-2y 81.5 (23.0) 92.9 (0, 100)
Adherence 0-2y 81.1 (22.2) 90.6 (7.4, 99.9)
�Data available for n = 58
https://doi.org/10.1371/journal.pone.0206009.t001
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first two years. With these splits, 32 children (34%) had a high adherence (�98% as cut-off
value) and 63 children (66%) a low adherence (<98% as cut-off value) in the first year. For the
second year, these figures were 50 (53%) for a high adherence (�91% as cut-off value) and 45
(47%) for a low adherence (<91% as cut-off value). For the first two years, these figures were
68 (72%) for a high adherence (�78% as cut-off value) and 27 (28%) children (<78% as cut-off
value).
Table 2 shows the results of the effect of adherence on ΔHSDS, the parameters of the growth
curves and IoR. Ten out of eighteen associations from the final model were statistically signifi-
cant. The strongest associations were found between high versus low adherence in the second
year and IoR 2y, between adherence (continuous, in %) and ΔHSDS 0-2y, and between high
versus low adherence in the first two years and ΔHSDS 0-2y. Mean SD) IoR at 2y was 0.19
(0.99) in the high adherence group and -0.44 (1.04) in the low adherence group. Without
adjustment, mean (SD) ΔHSDS 0-2y was +1.16 (0.52) in the high adherence group and +0.88
(0.41) in the low adherence group. After adjustment for the clinical confounders, the differ-
ence in mean height between the high and low adherence group increased from +0.28 SD to
+0.34 SD. The size of the effect of adherence (continuous) in the first two years on HSDS 0-2y
can be calculated by multiplying the model estimate by the percentage gain of adherence. For
example, a 14% lower adherence (missed 1 injection/week) in the first two years is associated
with 14 x 0.00792 = 0.11 SD less height gain, and a 28% lower adherence (missed 2 injections/
week) with 0.22 SDS less height gain.
Discussion
Our study is the first to show the effect of suboptimal adherence in a large group of patients
with GHD using a reliable method to automatically assess adherence through an electronic
device over the first two years of GH treatment (Easypod). The effect size of suboptimal adher-
ence is dependent on the percentage of missed injections; if a cut-off of 78% is used, the loss of
height gain was 0.34 SD, approximately 2–2.5 cm after two years of GH treatment.
It is noteworthy that average adherence in the first year was not associated with first year
growth response, in contrast to the second year and both years combined. We believe that
there are three explanations for this observation. The first is that average adherence in the first
year is very high with little variation, which limits the power to detect statistically significant
associations. Second, adherence has a skewed distribution, which may reduce the associations.
Third, the effect of GH on growth is most prominent in the first year of treatment, with a rela-
tively strong effect on growth velocity with relatively little effect of GH dose [3].
Our data show that in order to obtain a good insight into the effect of suboptimal adher-
ence, two conditions have to be met. First, an outcome parameter has to be used that repre-
sents the natural shape of CUG. In the first years of treatment, CUG has the shape of a sharp
increase of HSDS in the first year, followed by gradually decreasing height velocities until
HSDS adjusted for TH-SDS is close to 0. HSDS remains stable until the onset of puberty, when
the pubertal growth spurt begins. This implies that the choice for the outcome parameter is
dependent on the number of years after start of GH treatment. In the first years, growth should
be compared with a model for CUG, thereafter to a stable HSDS, and from pubertal onset the
effect of adherence becomes impossible to analyze because of interference by the pubertal
growth spurt. Our data show that over the first two years the change in HSDS gives similar or
higher effects than the growth rate parameters of the two mathematical models. Although the
cut-offs for adherence were based on the difference in HSDS, a similar cut-off for 0–2 y was
found for the slope parameter D. We propose that this outcome measure may be superior to
the various indicators of “poor response” reported in the literature [21].
Effect of adherence to growth hormone treatment on growth
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The second condition that has to be met is that sufficient adjustment is made for clinical
parameters that influence the growth response to GH treatment. In our study, adherence in
the first two years strongly correlated with height gain 0–2 y, even unadjusted for clinical pre-
dictors. However, the effect of adherence became considerably stronger when adjustment was
made to well established predictors.
While automatic recording of adherence is helpful to give insight into the frequency of sub-
optimal adherence and its effect on the growth response to GH treatment, for clinical care its
most important benefit could be that it gives the clinician a signal to intervene and try to
improve adherence. In theory, supportive accountability, including human support, motiva-
tional interviewing and communication “bandwidth” could be successful, and potentially suc-
cessful approaches have been suggested [22,23,24]. However, controlled trials on the efficacy
of such programs are lacking.
The limitations of this study include its non-interventional nature, which is associated with
a high level of missing data, high inter-patient variability, and the absence of detailed recording
of actions performed by health-care providers and carers when poor adherence and/or poor
Fig 2. Adherence in the first two years after starting growth hormone therapy.
https://doi.org/10.1371/journal.pone.0206009.g002
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response to treatment was recorded. However, these limitations occur in all surveillance stud-
ies [25], whereas the observational nature means that it reflects normal clinical practice.
Another limitation is that the cut-off values for defining a high and low adherence were con-
structed in the same dataset as the correlation analysis. This may have overestimated the corre-
lations. However, similar conclusions could be drawn based on the adjusted correlations
between ΔHSDS in the first, second and first two years and adherence in % (linear) and adher-
ence in two categories (high versus low according to the cut-off values that we developed).
Also, when we apply the Cutfield cut-off values [9] of high (�86%) versus low adherence
(<86%) in the first, second and first two years, similar significance levels were found with the
exception of ΔHSDS in the first two years (Adj. B (SE) = 0.23156 (0.12338), p = 0.066). The
cut-off value of�86% for a high adherence was chosen by Cutfield et al. [9], because it corre-
sponds to no more than one missed dose a week on average. However, it is to be preferred to
take the cut-off value that maximizes the correlation between adherence and height gain,
because it provides more insight into the doses that are needed per several days, week or sev-
eral weeks to have an optimal height gain. Further research is needed to investigate if the
Table 2. Results of linear regression analyses with ΔHSDS and the parameters of the growth curves as outcome and adherence as dependent variable with and with-
out adjustment for potential clinical confounders (n = 95).








ΔHSDS 0-1y Adherence 0-1y (high vs lowb) 0.19508 (0.07277)�� 0.15268 (0.06674)� 0.15281 (0.06741)� 0.156532 (0.086071)
Adherence 0-1y (in %) 0.00114 (0.00115) 0.00101 (0.00101) 0.00111 (0.00111) 0.00193 (0.00143)
ΔHSDS 1-2y Adherence 1-2y (high vs lowb) 0.13908 (0.05231)�� 0.15606 (0.05261)�� 0.15972 (0.05250)�� 0.15416 (0.05783)�
Adherence 1-2y (in %) 0.00254 (0.00115)� 0.00282 (0.00115)� 0.00294 (0.00115)� 0.00306 (0.00113)��
ΔHSDS 0-2y Adherence 0-2y (high vs lowb)^ 0.27744 (0.11175)� 0.29110 (0.09754)�� 0.33681 (0.10161)�� 0.34356 (0.12583)��
Adherence 0-2y (in %) 0.00465 (0.00230)� 0.00500 (0.00205)� 0.00596 (0.00216)�� 0.00792 (0.00253)��
Ac Adherence 0-2y (high vs lowb)^ 0.2199 (0.2356) 0.36290 (0.20320) 0.42619 (0.21318)� 0.38919 (0.26092)
Adherence 0-2y (in %) 0.00406 (0.00481) 0.00887 (0.00418)� 0.01053 (0.00441)� 0.01253 (0.00518) �
kc Adherence 0-2y (high vs lowb)^ 0.004739 (0.071399) -0.02255 (0.06929) -0.04837(0.07252) -0.06807 (0.08505)
Adherence 0-2y (in %) -0.00086 (0.00145) -0.00181 (0.00142) -0.00256 (0.00149) -0.00375 (0.00168)�
Dd Adherence 0-2y (high vs lowb)^ 0.22788 (0.07813)�� 0.23054 (0.06822)�� 0.24612 (0.07175)�� 0.224221 (0.091026)�
Adherence 0-2y (in %) 0.00318 (0.00163) 0.00324 (0.00146)� 0.00345 (0.00155)� 0.00408 (0.00189)�
Ed Adherence 0-2y (high vs lowb)^ 0.05306 (0.02061)� 0.05134 (0.01975)� 0.04698 (0.02077)� 0.03313 (0.02403)
Adherence 0-2y (in %) -0.00061 (0.00043) -0.00056 (0.00042) -0.00041 (0.00044) -0.00030 (0.00050)
IoRe 1y Adherence 0-1y (high vs lowb) 0.5456 (0.2442)�
Adherence 0-1y (in %) -0.00299 (0.00381)
IoRe 2y Adherence 1-2y (high vs lowb) 0.6237 (0.2078)��
Adherence 1-2y (in %) 0.00882 (0.00466)
aModel 1: Adherence
Model 2: Model 1 + age at start + adj-HSDS at start + birth weight SDS + gestational age (<37 weeks vs�37 weeks)
Model 3: Model 2 + GH dose
Model 4: Model 3 + GH max (n = 58)
bhigh�98%, low<98% adherence 0-1y, high�91%, low<91% adherence 1-2y, high�78%, low<78% adherence 0-2y
^Both adherence in the first and second year in the model
cParameters of the monomolecular growth curve: A-5 = attained adj-HSDS after two years-5, A�(1-B)-5 = adj-HSDS at start, k = growth rate.
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performance of the constructed cut-off values in our study provides similar correlations between
high/low adherence and height gain in new datasets compared to our study. Another limitation of
our study is that we did not include IGF-I measurements to assess GH status and predict growth
response and adherence during GH therapy in our patients. IGF-I measurements were not avail-
able for the majority of patients, because ECOS was a surveillance study [26]. For this study, we
only selected adherence from the easypod electronic drug-delivery device, growth outcomes and
several clinical and background parameters as potential confounders.
Strengths include that it is the first study that has used a device with an eHealth platform to
report adherence data directly from patients to health-care providers. A number of individual
cases from ECOS have been reported [27,28,29,30]; these indicate that direct access to adher-
ence monitoring can make the difference in a patient’s management and motivation. For
example, a 14% lower adherence (missed 1 injection/week) in the first two years is associated
with 14 x 0.00792 = 0.11 SD less height gain, and a 28% lower adherence (missed 2 injections/
week) with 0.22 SDS less height gain.
The success of therapy depends mainly on the ability of the patients and their parents to care-
fully adhere to the recommended treatment regimen. Complex schedules should be avoided. This
study shows that each missed injection/week in the first two years resulted in 0.11 SD less height
gain, which implies that a daily routine of taking an injection, especially in the second year, is rec-
ommended. Although accurate and up-to-date adherence data can be obtained from the easypod-
device, at the moment this data is not directly available for the physician. So complete non-
adherence to GH therapy is relatively easy to detect on the basis of growth failure, but suboptimal
and/or intermittent adherence are more difficult to assess. Linking the adherence data from the
easypod device to the physician can be helpful in the future. At the moment, regularly interview-
ing the patients and their parents are efficacious means of detecting the degree of adherence [31].
Different strategies can be incorporated to enhance adherence to GH therapy, i.e. providing early
patient and parent education and support, medication reminder systems and longer duration of
GH prescriptions [32]. A personalized approach seems to be promising, because a previous study
on the ECOS data showed that several clinical parameters and background characteristics of the
patients are important determinants to predict the level of adherence. Early age of self-administra-
tion, weight at start of treatment, and teenage years are associated with a lower adherence to GH
treatment [33]. Patient adherence support programs that take into account these factors may
improve adherence and subsequent clinical outcomes. Further studies are required to design per-
sonalized patient support programs to attain and maintain good adherence to GH treatment.
In conclusion, electronically monitoring adherence enables obtaining reliable information
on adherence in a “real-life” situation, and shows a statistically significant effect on the growth
response in the first two years of treatment in children with GHD. Each missed injection per
week in the first two years, resulted in 0.11 SDS less height gain. The next step should be to
develop interventional tools to explore the hypothesis that patient adherence support pro-
grams improve adherence and subsequent clinical outcomes.
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